[go: up one dir, main page]

SE9801368D0 - New use - Google Patents

New use

Info

Publication number
SE9801368D0
SE9801368D0 SE9801368A SE9801368A SE9801368D0 SE 9801368 D0 SE9801368 D0 SE 9801368D0 SE 9801368 A SE9801368 A SE 9801368A SE 9801368 A SE9801368 A SE 9801368A SE 9801368 D0 SE9801368 D0 SE 9801368D0
Authority
SE
Sweden
Prior art keywords
value
glucocorticosteroid
reversibility
copd
patients
Prior art date
Application number
SE9801368A
Other languages
Swedish (sv)
Inventor
Ralph Brattsand
Stefan Ohlsson
Carl Goeran Persson
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9801368A priority Critical patent/SE9801368D0/en
Publication of SE9801368D0 publication Critical patent/SE9801368D0/en
Priority to BR9909786-9A priority patent/BR9909786A/en
Priority to PCT/SE1999/000426 priority patent/WO1999053926A1/en
Priority to CA002329008A priority patent/CA2329008A1/en
Priority to JP2000544330A priority patent/JP2002512193A/en
Priority to HK02100375.3A priority patent/HK1038703A1/en
Priority to AU30625/99A priority patent/AU3062599A/en
Priority to CN99807636A priority patent/CN1306429A/en
Priority to EP99912204A priority patent/EP1073441A1/en
Priority to ARP990101816A priority patent/AR018191A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of a glucocorticosteroid for the manufacture of a medicament for treating chronic obstructive pulmonary disease (COPD) in patients having an FEV1.0 value > 65 % of predicted value and < 10 % reversibility in bronchodilator test. The invention further relates to a method for treatment of COPD in patients having an FEV1.0 value > 65 % of predicted value and < 10 % reversibility in bronchodilator test, where a therapeutically effective amount of a glucocorticosteroid is administered to a patient in need of such treatment.
SE9801368A 1998-04-20 1998-04-20 New use SE9801368D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9801368A SE9801368D0 (en) 1998-04-20 1998-04-20 New use
BR9909786-9A BR9909786A (en) 1998-04-20 1999-03-18 Use of a glucocorticosteroid to manufacture a drug to treat mild / early forms of copd (chronic obstructive pulmonary disease
PCT/SE1999/000426 WO1999053926A1 (en) 1998-04-20 1999-03-18 Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)
CA002329008A CA2329008A1 (en) 1998-04-20 1999-03-18 Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)
JP2000544330A JP2002512193A (en) 1998-04-20 1999-03-18 Use of carbohydrate corticosteroids for the manufacture of a medicament for treating mild / early forms of COPD (chronic obstructive pulmonary disease)
HK02100375.3A HK1038703A1 (en) 1998-04-20 1999-03-18 Use of a gluococorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)
AU30625/99A AU3062599A (en) 1998-04-20 1999-03-18 Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)
CN99807636A CN1306429A (en) 1998-04-20 1999-03-18 Use of glucocorticosteriod for mfg. medicament for treating mild/early forms of COPD (chronic obstructive pulmonary disease)
EP99912204A EP1073441A1 (en) 1998-04-20 1999-03-18 Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)
ARP990101816A AR018191A1 (en) 1998-04-20 1999-04-20 USE OF GLUCOCORTICOSTEROIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801368A SE9801368D0 (en) 1998-04-20 1998-04-20 New use

Publications (1)

Publication Number Publication Date
SE9801368D0 true SE9801368D0 (en) 1998-04-20

Family

ID=20411015

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9801368A SE9801368D0 (en) 1998-04-20 1998-04-20 New use

Country Status (10)

Country Link
EP (1) EP1073441A1 (en)
JP (1) JP2002512193A (en)
CN (1) CN1306429A (en)
AR (1) AR018191A1 (en)
AU (1) AU3062599A (en)
BR (1) BR9909786A (en)
CA (1) CA2329008A1 (en)
HK (1) HK1038703A1 (en)
SE (1) SE9801368D0 (en)
WO (1) WO1999053926A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912534D0 (en) 1999-05-29 1999-07-28 Glaxo Group Res Ltd Novel prognostic surrogate
ECSP003747A (en) * 1999-11-02 2002-05-23 Smithkline Beecham Corp METHOD AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES
CA2508692C (en) 2002-12-12 2012-04-03 Altana Pharma Ag Combination medicament
WO2004070058A1 (en) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of copd
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
WO2005025578A1 (en) 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
JP2007533706A (en) * 2004-04-20 2007-11-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of ciclesonide for the treatment of respiratory diseases in smoking patients

Also Published As

Publication number Publication date
CN1306429A (en) 2001-08-01
EP1073441A1 (en) 2001-02-07
CA2329008A1 (en) 1999-10-28
JP2002512193A (en) 2002-04-23
AR018191A1 (en) 2001-10-31
WO1999053926A1 (en) 1999-10-28
HK1038703A1 (en) 2002-03-28
BR9909786A (en) 2000-12-19
AU3062599A (en) 1999-11-08

Similar Documents

Publication Publication Date Title
AU684087B2 (en) Use of modafinil for the treatment of sleep apnoea and ventilation problems of central origin
CY1105199T1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF MUCUS DISCHARGE
ATE252912T1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNCTIONAL DYSPEPSIA AND/OR IRGITABLE BOWEL SYNDROME AND THE USE OF NEW SUBSTANCES IN THIS COMPOSITION
KR950002785A (en) Parathyroid hormone and raloxyphene to increase bone mass
BR0008276A (en) Combinations of formoterol and fluticasone propionate for asthma
Wang et al. Adding corticosteroids to periarticular infiltration analgesia improves the short-term analgesic effects after total knee arthroplasty: a prospective, double-blind, randomized controlled trial
BR0015974A (en) Use of levetiracetam, pharmaceutical composition, use of a pharmaceutical composition and methods to treat a patient administered with an amount of at least one compound and a disease and to selectively potentiate the therapeutic effect of a compound
ATE330589T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING RESVERATROL FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY TRACT
BR0111591A (en) Compounds, pharmaceutical composition, and methods for elevating the growth hormone plasma level in a mammal, for the treatment of growth hormone secretion deficiency, for the treatment of growth retardation in children, for the treatment of metabolic disorders growth hormone secretion deficiency, particularly in elderly patients, and to promote wound healing, surgical recovery or recovery from debilitating diseases
EA200700232A1 (en) HIGH-SELECTIVE INHIBITORS OF REVERSE CAPTURE OF NOREPINEFRIN AND METHODS OF THEIR APPLICATION
BR9811825A (en) Use of lactobacillus to reduce the level of fibrinogen in the blood
Elhakim et al. Effects of intraperitoneal lidocaine combined with intravenous or intraperitoneal tenoxicam on pain relief and bowel recovery after laparoscopic cholecystectomy
BR9713921A (en) Compound, pharmaceutical composition, process for logician capable of being modulated through factor xa inhibition
SE9801368D0 (en) New use
WO2004100878A3 (en) Method of treatment of hemorrhagic disease using a factor viia/tissue factor inhibitor
DE69424777D1 (en) 3,4-DIARYLCHROMANE FOR TREATING DERMATITIS
MXPA03011702A (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases.
Harper et al. Non-union of Colles' fracture: report of two cases
BR9809678A (en) Triptolyte derivatives useful in the treatment of autoimmune diseases
WO2002039999B1 (en) Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
BR9809673A (en) Triptolide derivatives useful in the treatment of autoimmune diseases
Ejnell et al. Treatment of postoperative pain with diclofenac in uvulopalatopharyngoplasty
SE9902597D0 (en) New use
EA200200518A1 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF PULMONARY DISEASES
RU98114080A (en) BIOLOGICALLY ACTIVE ETHANAMINES OF BENZOTIAZOLONE